- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04153786
Effect of Cardiac Resynchronization Therapy (CRT) on Left Ventricular Assist Device (LVAD) Function
Certain patients with congestive heart failure are treated both by implantation of an LVAD, as well as implantation with a biventricular pacemaker. Both of these devices, individually, have been shown to improve the health of patients with heart failure. However, only a small number of patients have both an LVAD and a biventricular pacemaker at the same time.
Pacemakers have many different settings. However, there is little data to inform physicians which of these different settings is best for the flow of an LVAD. This study is evaluating patients who have both a biventricular pacemaker and an LVAD. Investigators will operate the pacemaker at multiple different settings and monitor the LVAD's function to determine which, if any, setting is best for the LVAD's flow.
Study Overview
Status
Intervention / Treatment
Detailed Description
Cardiac resynchronization therapy (CRT) with a biventricular pacemaker has been well-validated to improve symptoms and reduce death in select patients with heart failure. In healthy adults, the two chambers of the heart which pump blood throughout the body (the left and right ventricles) activate and contract together in synchronous fashion. In certain patients with heart failure (specifically, those with a reduced ejection fraction), the left and right ventricles no longer activate and contract synchronously. CRT restores ventricular synchrony by simultaneously activating the left (LV) and right ventricles (RV) with electrical pacing.
Left ventricular assist devices (LVADs) are used to provide mechanical support to patients with more advanced, often end-stage, heart failure. In these cases, the heart's ventricles function so poorly that even despite all standard therapies (including CRT), patients experience symptoms of congestive heart failure even at rest. The LVAD suctions blood from the ventricle and propels it into the aorta, offloading the ventricle and assisting its function.
Due to the similar reasons for using each therapy, a number of patients already possess a biventricular pacemaker at the time of LVAD implantation. Individually, each intervention is known to improve both patient survival and functional status. However, there is sparse data to evaluate the effectiveness of using both devices simultaneously. Specifically, no data is yet available assessing the effect of CRT on the functional parameters of the LVAD.
This protocol will operate the biventricular pacemaker at various settings and assess for changes in the LVAD's function in response to those settings. "Fine-tuning" and identifying the ideal the pacemaker settings will maximize clinical benefit in patients with both devices.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hannah M Bernstein, MD
- Phone Number: 2024135486
- Email: hmbernstein@ucdavis.edu
Study Contact Backup
- Name: Uma Srivatsa, MD
- Phone Number: 9167343764
- Email: unsrivatsa@ucdavis.edu
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- University of California Davis Medical Center
-
Contact:
- Hannah M Bernstein, MD
- Phone Number: 202-413-5486
- Email: hmbernstein@ucdavis.edu
-
Contact:
- Roshni V Khatiwala, MD
- Phone Number: 2016696474
- Email: rkhat@ucdavis.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients who have undergone implantation of both a biventricular pacemaker and LVAD who are at least three months post-LVAD implantation and who receive routine follow-up care at the UC Davis / UC San Diego Adult Arrhythmia/ Device/ LVAD clinic.
- Potential enrollees have been directly identified by their existing medical providers in clinic, who are investigators in this study.
Exclusion Criteria:
- Any patients who do not present to their routine follow-up appointment at the time of this study.
- Any patients who have undergone LVAD placement less than three months prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort
Pacemakers will be programmed to BiV pacing, left ventricular (LV) pacing, right ventricular (RV) pacing and no pacing for five minutes each.
LVAD flow will be recorded every thirty seconds for five minutes with each setting.
Once the interventions have been completed, all pacemakers will be returned to their original setting.
|
During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD. The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD. However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LVAD flow
Time Frame: 2-5 minutes
|
Flow is the liters per minute (L/min) of blood moved by the device.
|
2-5 minutes
|
LVAD power
Time Frame: 2-5 minutes
|
Power is the voltage required by the device over each cardiac cycle.
|
2-5 minutes
|
LVAD speed
Time Frame: 2-5 minutes
|
LVAD speed, or revolutions per minute (RPMs) of the device, is set by providers to a fixed value.
|
2-5 minutes
|
LVAD pulsatility index (PI)
Time Frame: 2-5 minutes
|
LVAD PI reflects the contribution of the native heart's cardiac output (or "pulse") on pump flow
|
2-5 minutes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Uma Srivatsa, MD, UC Davis
- Principal Investigator: Martin Cadeiras, MD, UC Davis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1403080
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on LVAD (Left Ventricular Assist Device) Driveline Infection
-
University of California, San FranciscoInternational Consortium of Circulatory Assist CliniciansRecruitingLVAD (Left Ventricular Assist Device) Driveline InfectionUnited States
-
University Hospital Inselspital, BerneCompletedLeft Ventricular Assist DeviceSwitzerland
-
Institute for Clinical and Experimental MedicineRecruiting
-
Abbott Medical DevicesThoratec Europe LtdCompletedAnticoagulation | Left Ventricular Assist DeviceUnited States, Austria, France, Germany, Czechia
-
National Taiwan University HospitalCompletedPhysical Therapy | Left Ventricular Assist DeviceTaiwan
-
University of MinnesotaWithdrawnHeart Failure | Left Ventricular Assist Device | Intra-aortic Balloon Pump | LVAD Clot | LVAD-related GI BleedUnited States
-
Karol WierzbickiMedtronic Poland Spółka z ograniczoną odpowiedzialnością; Cor Aegrum Foundation... and other collaboratorsCompletedLeft Ventricular Assist DevicePoland
-
Abbott Medical DevicesThoratec CorporationCompletedLeft Ventricular Assist Device | Percutaneous Lead ManagementUnited States
-
Universitätsklinikum KölnNot yet recruitingVentricular Tachycardia | Ventricular Arrythmia | End-stage Heart Failure | LVAD (Left Ventricular Assist Device)
-
Rigshospitalet, DenmarkRecruitingHeart Failure | Prognosis | Left Ventricular Assist Device | Durable Mechanical Support DeviceDenmark